(Q48471185)

English

Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.

scientific article published on 18 May 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

enzyme replacement therapy

0 references

author name string

Takashi Higuchi

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Hiromi Shimizu

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Takahiro Fukuda

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Shiho Kawagoe

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Juri Matsumoto

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Yohta Shimada

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Hiroshi Kobayashi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Hiroyuki Ida

8

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Toya Ohashi

9

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Hideto Morimoto

10

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Tohru Hirato

11

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Katsuya Nishino

12

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Yoshikatsu Eto

13

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

publication date

18 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

107

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

1-2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

122-128

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Enzyme replacement therapy for Pompe disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Mucopolysaccharidosis VI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Y-maze behavior in the mouse after morphine or an enkephalin analog

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Skin eruption as the presenting sign of Hunter syndrome IIB

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

[Clinical aspects of early-stage neurological forms of Gaucher disease]

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Metachromatic leukodystrophy--an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Initial report from the Hunter Outcome Survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.05.005

7 January 2021

Identifiers

10.1016/J.YMGME.2012.05.005

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

release_ocsbchljn5c6reofuemhr6cmya

1 reference

https://api.fatcat.wiki/v0/release/ocsbchljn5c6reofuemhr6cmya

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22704483

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48471185&oldid=1840232946"